[Articles] Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16 –26 years: a randomised, double-blind trial

The 9vHPV vaccine prevents infection, cytological abnormalities, high-grade lesions, and cervical procedures related to HPV 31, 33, 45, 52, and 58. Both the 9vHPV vaccine and qHPV vaccine had a similar immunogenicity profile with respect to HPV 6, 11, 16, and 18. Vaccine efficacy was sustained for up to 6 years. The 9vHPV vaccine could potentially provide broader coverage and prevent 90% of cervical cancer cases worldwide.

Source: LANCET - September 5, 2017 Category: General Medicine Authors: Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-H élène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleto Tags: Articles Source Type: research